http://www.cnr.it/ontology/cnr/individuo/prodotto/ID27640

Exon skipping-mediated dystrophin reading frame restoration for small mutations. (Articolo in rivista)

Type

Label

Exon skipping-mediated dystrophin reading frame restoration for small mutations. (Articolo in rivista) (literal)

Anno

Alternative label

Spitali P, Rimessi P, Fabris M, Perrone D, Falzarano S, Bovolenta M, Trabanelli C, Mari L, Bassi E, Tuffery S, Gualandi F, Maraldi NM, Sabatelli-Giraud P, Medici A, Merlini L, Ferlini A. (2009)
Exon skipping-mediated dystrophin reading frame restoration for small mutations.
in Human mutation
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Spitali P, Rimessi P, Fabris M, Perrone D, Falzarano S, Bovolenta M, Trabanelli C, Mari L, Bassi E, Tuffery S, Gualandi F, Maraldi NM, Sabatelli-Giraud P, Medici A, Merlini L, Ferlini A. (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Italy; Department of Chemistry, University of Ferrara, Ferrara, Italy; Department of Biology and Evolution, University of Ferrara, Ferrara, Italy; Universite Montpellier 1, Faculte de Medecine and Inserm, U827, Montpellier, F-34000, France; Institute of Anatomy, University of Bologna; IGM-CNR., Unit of Bologna, c/o IOR, Bologna, Italy (literal)

Titolo

Exon skipping-mediated dystrophin reading frame restoration for small mutations. (literal)

Abstract

Exon skipping using antisense oligonucleotides (AONs) has successfully been used to reframe the mRNA in various Duchenne muscular dystrophy patients carrying deletions in the DMD gene. In this study we tested the feasibility of the exon skipping approach for patients with small mutations in in-frame exons. We first identified 54 disease-causing point mutations. We selected five patients with nonsense or frameshifting mutations in exons 10, 16, 26, 33, and 34. Wild-type and mutation specific 2'OMePS AONs were tested in cell-free splicing assays and in cultured cells derived from the selected patients. The obtained results confirm cell-free splicing assay as an alternative system to test exon skipping propensity when patients' cells are unavailable. In myogenic cells, similar levels of exon skipping were observed for wild-type and mutation specific AONs for exons 16, 26, and 33, whereas for exon 10 and exon 34 the efficacy of the AONs was significantly different. Interestingly, in some cases skipping efficiencies for mutated exons were quite dissimilar when compared with previous reports on the respective wild-type exons. This behavior may be related to the effect of the mutations on exon skipping propensity, and highlights the complexity of identifying optimal AONs for skipping exons with small mutations. (literal)

Prodotto di